Harrow Health signs agreement to acquire certain comercial rights from Santen

Harrow announced the signing of agreements with affiliates of Santen Pharmaceutical under which Harrow will acquire certain U.S. and Canadian commercial rights for the following branded products from Santen. U.S. Products include: FLAREX, or fluorometholone acetate ophthalmic suspension; NATACYN, or natamycin ophthalmic suspension; TOBRADEX ST, or tobramycin and dexamethasone ophthalmic suspension; VERKAZIA, or cyclosporine ophthalmic emulsion; ZERVIATE, or cetirizine ophthalmic solution; and FRESHKOTE, used as a lubricant to reduce further irritation or to relieve dryness of the eye. Canadian products include: VERKAZIA, or cyclosporine ophthalmic emulsion; Cationorm PLUS, a preservative-free emulsion for the treatment of dry eye symptoms and for the treatment of signs and symptoms of ocular allergy. Financing for the transaction was provided through the expansion of Harrow’s secured credit facility with funds managed by Oaktree Capital Management. Harrow management expects the transaction to reduce the Company’s aggregate leverage ratio of adjusted EBITDA to debt.